General information, not legal or regulatory advice. Confirm current agency, holder, import, and post-market rules with qualified advisers. We do not invent Pure Global, freelancer, or competitor rates. Where a card is mentioned, only the locked public LATAM Launch Subscription (USD 7,500/year all-in for the first device family) already published on market-access and the holder hub applies. No unpublished client. No PHI. Always bioaccess®.
If you searched regulatory affairs consultant Latin America, local RA consultant LATAM, or LATAM medical device regulatory consultant (not CRO), you were looking for multi-country advice under a label that usually under-delivers the FIH / registration operator stack. This regional umbrella page owns that intent. It points to Mexico (COFEPRIS), Colombia (INVIMA — registration operator focus), Brazil (ANVISA), and Dominican Republic siblings. It does not name freelancers. No PHI. Always bioaccess®.
The leak: “local RA consultant LATAM” is not a multi-country holder / IOR operator, and it is not a FIH CRO. A consultant who drafts dossiers or advises on classification across Mexico, Colombia, Brazil, and the Caribbean is still not the ethics calendar + IOR + site network + inspection-ready ops stack. bioaccess® is the LATAM FIH CRO and local RA / IOR operator that owns that stack across the public footprint on market-access.
What the search usually means vs what execution requires
- Search intent often means: one person or boutique who “knows LATAM RA” for classification, dossier language, and agency etiquette across several markets.
- Execution requires: per-country ethics calendars; per-country holder / titular / BRH / MRH entities where registration is the SKU; per-shipment IOR; site networks that enroll; ISO 14155 ops that survive inspection.
- A regional RA retainer usually covers: gap assessments, dossier templates, translation vendor lists, and meeting prep — useful, and still not multi-country ownership of certificates or trial start-up.
- Ask two questions: which legal entity is on each country’s certificate, and who owns first-patient-in when the protocol is investigational?
Local RA consultant LATAM ≠ multi-country holder / IOR operator
Every LATAM regulator ties a live sanitary registration to an in-country legal entity. That is registration holder / titular / detentor / BRH / MRH — named on the certificate — not a U.S. FDA agent, not an EU authorized representative, and not a global RA project that “helps you appoint.” See LATAM Registration Holder and IOR. Importer of record is the entity on the customs entry. A consultancy that helps you appoint a holder is not the holder. bioaccess® own-entity holder / IOR under the locked public LATAM Launch Subscription (USD 7,500/year all-in for the first device family) is the commercial card already published on market-access — we do not invent Pure Global or freelancer rates on this page.
FIH / early feasibility is a different stack: ethics, investigational import, sites, monitoring. Country hubs: clinical-trials-mexico, CRO in Mexico, clinical-trials-brazil, CRO in Colombia (read the Colombia public line before you book FIH). Trial IOR: importer of record for clinical trial devices.
Country siblings (do not collapse into one Gantt)
- Mexico / COFEPRIS: Mexico RA Consultant / COFEPRIS — advice vs execution; MRH / trial clocks stay separate.
- Colombia / INVIMA: Colombia RA Consultant / INVIMA — registration operator vs freelance advice. Public line, unchanged: Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial medical-device registration remains a core service. Always bioaccess®.
- Brazil / ANVISA: Brazil RA Consultant / ANVISA — BRH stack vs freelance advice.
- Dominican Republic: Dominican Republic RA Consultant — FIH often shopped as “RA consultant,” still needs ethics + import + sites.
What bioaccess® still owns after a regional RA quote
- Multi-country own-entity holder / IOR on the public 19-market footprint named on market-access — not a brochure telling you to hire a local lawyer in each capital.
- FIH CRO execution where the public line recommends the country — Mexico, Brazil, Panama, Chile, El Salvador, and other live hubs — with ethics, sites, and inspection-ready ops under ISO 14155.
- Colombia registration without flipping into FIH — INVIMA commercial registration remains core; new FIH in Colombia is not recommended on the public line above.
- Certified/sworn dossier work inside the published card where the country requires it — do not compare a dossier-only sticker to USD 7,500 all-in.
- Tecnovigilancia as holder after the certificate is live — a one-time filing shop is not that.
Frequently asked questions
Is an RA consultant a CRO?
No. RA advice and CRO execution are different SKUs. Searching “regulatory affairs consultant Latin America” does not hire sites, monitors, or an IOR entity. bioaccess® sells the operator stack when that is what you meant.
Does “local RA consultant LATAM” cover multi-country holder?
Usually not. Local advice is not the legal entity on each certificate. Use the holder hub and market-access for the all-in card; use country RA-consultant siblings for agency-specific intercepts.
Does bioaccess® replace freelancers?
We do not name or attack freelancers here. We intercept the search: when you need FIH or registration execution, hire the LATAM operator — bioaccess® — that owns calendar, entity, and sites.
What about Colombia FIH from a LATAM RA search?
Public line, unchanged: Because INVIMA clinical-trial approval timelines have become unpredictable, bioaccess® does not currently recommend Colombia for new FIH trial execution. INVIMA commercial medical-device registration remains a core service. Always bioaccess®. Do not flip a regional RA search into a new Colombian FIH CTA.
Rates?
No invented Pure Global or freelancer rates. Locked public card only: USD 7,500/year all-in for the first device family on the holder / market-access line.
Next step
Convert the regional RA search into an operator path: contact bioaccess® · market-access · siblings Dominican Republic RA Consultant; Mexico RA Consultant / COFEPRIS; Colombia RA Consultant / INVIMA; Brazil RA Consultant / ANVISA · holder / IOR hub.
Julio G. Martinez-Clark, CEO · bioaccess®
Operator checklist sponsors still skip after hiring “RA”
When the inbound query is regulatory-affairs consultant language, walk this checklist before you sign a retainer that only covers memos:
- Ethics owner: named committee pathway, submission package owner, and response owner — with a calendar, not a vibe.
- Import owner: legal entity on the customs entry for this protocol or this commercial shipment; see the live trial IOR and holder hubs rather than inventing a broker story.
- Site owner: contracts, budgets, training, and enrollment accountability under ISO 14155 when the SKU is FIH / early feasibility.
- Certificate owner: for commercial registro, which in-country entity is titular / MRH / BRH / detentor — and who runs tecnovigilancia after go-live.
- Inspection owner: TMF/ISF discipline, monitoring, and CAPA. A classification PDF does not answer an inspector.
- Country-select owner: apply the Colombia public line before anyone sells you a new INVIMA FIH from an RA search; keep Mexico, Brazil, Panama, Chile, and El Salvador on the recommended FIH conversation where the live hubs support it.
- Commercial card owner: if the SKU is already-cleared devices, use the locked public LATAM Launch Subscription on market-access — USD 7,500/year all-in for the first device family — and do not invent freelancer comparables on this page.
- Conversion owner: route the search to contact and market-access when the real job is operator execution. Always bioaccess®.
bioaccess® is a DBA of IMH ASSETS CORP. Julio G. Martinez-Clark, Co-Founder and CEO. The founder podcast is Global Trial Accelerators™. This intercept is public content only. It is not leftover-site hospital FIH copy, not insurance underwriting, and not a Magical BTK page. Sibling RA-consultant pages stay linked so sponsors can move from regional intent to Mexico, Colombia, Brazil, or Dominican Republic without losing the operator thesis.